Navigation Links
Vortex Biosciences Appoints Dr. Massimo Cristofanilli As Chairman of Newly Formed Scientific Advisory Board

Vortex Biosciences, provider of circulating tumor cell (CTC) enrichment systems, today announced the appointment of Dr. Massimo Cristofanilli as the Chairman of its newly formed Scientific Advisory Board (SAB). The SAB's mission will be to provide valuable scientific and clinical insights, along with strategic guidance in decision-making to support the development and commercialization of Vortex’s CTC enrichment system for both the research and diagnostic markets.

"Dr. Cristofanilli brings deep expertise in the clinical application of liquid biopsies," said Gene Walther, Chief Executive Officer of Vortex Biosciences "We are excited he is willing to chair our scientific advisory board and help us define our clinical strategy as we commercialize our next generation CTC enrichment system, the VTX-1,."

Massimo Cristofanilli, MD, an expert in the translational research and treatment of patients with inflammatory breast cancer (IBC), is Professor of Medicine in the Division of Hematology & Oncology at the Robert H Lurie Comprehensive Cancer Center, Northwestern University-Feinberg School of Medicine. Dr. Cristofanilli has led the development of novel diagnostic and prognostic markers in primary and metastatic breast cancer. His research is focused on advancing a patient-centered, biology driven model of cancer care; combining sophisticated tissue and blood-based molecular diagnostic technologies and innovative treatments. Prior to joining the Lurie Cancer Center, Dr. Cristofanilli was Director of the Breast Care Center and Deputy Director for Translational Research at the Sidney Kimmel Cancer Center at Thomas Jefferson University. He previously served as Chair of the Department of Medical Oncology at Fox Chase Cancer Center, and Executive Director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic at the University of Texas MD Anderson Cancer Center.

About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company that integrates cancer biology, microfluidic engineering and informatics to develop tools for isolating and characterizing circulating tumor cells. The Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient’s treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. Vortex is a core subsidiary of NetScientific plc, a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercializing technologies that significantly improve the health and well-being of people with chronic diseases. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vortex Biosciences Inventor Receives Presidential Award for Research Leading to Groundbreaking "Liquid Biopsy" Technique
2. Proove Biosciences Appoints John Steiner to Board of Directors
3. The ART BMC System by Celling Biosciences Is Revolutionizing the Practice of Cell Therapy
4. Proove Biosciences Acquires Algynomics, Inc.
5. Proove Biosciences Announces Strategic Partnership with McGill University to Study Link between Pain and Genetics
6. Dr. Nancy Gillett Joins Flagship Biosciences' Board of Directors
7. Rancho BioSciences Announces Services Around Open Clinica to Monitor Clinical Trial Data
8. Proove Biosciences and Specialty Health Announce a Positive Coverage Determination by Leading Nevada Insurer for Genetic Testing
9. EY Announces Brian Meshkin, CEO at Proove Biosciences, as EY Entrepreneur Of The Year® 2016 Orange County Semifinalist for the 2nd Year in a Row
10. Nerium International Partners with Signum Biosciences for Exclusive Use of SIG-1191™
11. Proove Biosciences Launches Expanded Drug Metabolism Profile to Help Doctors Prescribe Heart Medications with Greater Precision
Post Your Comments:
(Date:6/3/2020)... , ... June 03, 2020 , ... ... highlight various applications of biofeedback. In the next installment, Dr. Inna Khazan will ... whereby individuals learn to bring their attention to the feelings, thoughts, and emotions ...
(Date:5/30/2020)... ... May 29, 2020 , ... The Conference Forum is pleased ... dedicated to the unique role of the Chief Medical Officer in the biotech ... problem-solving, best practices and career development of CMOs and Heads of R&D from ...
(Date:5/26/2020)... MENLO PARK, Calif. (PRWEB) , ... May 26, 2020 , ... ... Genie , the most recognized brand of smart garage door openers, announce a new ... full line of Wi-Fi enabled garage door openers powered by Aladdin Connect® can now ...
(Date:5/21/2020)... , ... May 19, 2020 , ... Eaton Square is ... addition of Popper and Company, a biotechnology and medical technology-focused strategy and M&A advisory ... grow in the United States, linking US and Asia Pacific healthcare innovators with capital ...
Breaking Biology Technology:
(Date:6/25/2020)... ... 2020 , ... eClinical Solutions LLC , a leading ... drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on randomized ... COVID-19. This is the first study of an XPO1 inhibitor in patients with ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... is pleased to announce the next event in a series of TOPIQ webinars, ... The TOPIQ series of webinars was developed in response to social distancing measures ...
(Date:6/19/2020)... , ... June 18, 2020 , ... Join experts from ... PhD, Principal Scientist in a live webinar on Wednesday, July 8, 2020 ... simplified the way we genetically engineer new models. However, while modifying the genome may ...
Breaking Biology News(10 mins):